Jama Pitman is SVP & Chief Development Officer at Deciphera Pharmaceuticals, Inc. (DCPH). They have made 9 open-market trades across 1 company since 2022, most recently 2024-06-11.
CIK 0001852595
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 9 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DCPH | 60,298 | $1.5M |
| PrivateUnlisted | 88,194 | — |
| Total | $1.5M |
Shares reported on the most recent Form 4, priced at the 2024-06-11 close. 1 holding could not be priced and is excluded from the total.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DCPH | SELL | 2024-02-16 | 2024-02-20 | $15.62 | $35K | +12.9% | +0.8% | +65.6% |
| DCPH | SELL | 2024-01-16 | 2024-01-18 | $14.47 | $23K | +3.2% | +12.0% | +6.0% |
| DCPH | SELL | 2023-12-13 | 2023-12-14 | $15.37 | $26K | -0.1% | -10.0% | -0.5% |
| DCPH | SELL | 2023-10-30 | 2023-10-31 | $12.02 | $17K | -4.1% | +5.1% | +24.6% |
| DCPH | SELL | 2023-06-16 | 2023-06-21 | $14.40 | $18K | -5.2% | -7.4% | -5.4% |
| DCPH | SELL | 2023-02-16 | 2023-02-17 | $15.10 | $18K | -0.3% | +6.5% | -4.8% |
| DCPH | SELL | 2023-01-17 | 2023-01-19 | $21.24 | $34K | -14.6% | -27.1% | -22.9% |
| DCPH | SELL | 2022-06-16 | 2022-06-21 | $10.75 | $14K | +9.9% | +12.0% | +54.2% |
| DCPH | SELL | 2022-02-16 | 2022-02-18 | $9.05 | $10K | -5.9% | +12.1% | +43.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.